Severe piperacillin–tazobactam‐induced hemolysis in a cystic fibrosis patient

Piperacillin–tazobactam is one of the most common causes of drug‐induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life‐threatening piperacillin–tazobactam‐associated DIIHA in a 30‐year‐old woman with CF an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerkhoff, Andrew D., Patrick, Lauren, Cornett, Patricia, Kleinhenz, Mary‐Ellen, Brondfield, Sam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715418/
https://www.ncbi.nlm.nih.gov/pubmed/29225856
http://dx.doi.org/10.1002/ccr3.1256
Descripción
Sumario:Piperacillin–tazobactam is one of the most common causes of drug‐induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life‐threatening piperacillin–tazobactam‐associated DIIHA in a 30‐year‐old woman with CF and propose management recommendations for piperacillin–tazobactam‐associated DIIHA in CF patients.

Ejemplares similares